Morgan Stanley notes that Hims & Hers beat in Q4 and guided Q1 and calendar year 2025 revenue significantly above the Street consensus.

Hims & Hers on Monday released fourth-quarter results that disappointed on gross margin and sparked concerns about the future ...

Morgan Stanley cut shares of Hims & Hers Health (NYSE:HIMS – Free Report) from an overweight rating to an equal weight rating ...

In a report released today, Korinne Wolfmeyer from Piper Sandler maintained a Hold rating on Hims & Hers Health (HIMS – Research Report), ...

Healthcare stock Hims and Hers (HIMS) is sharply lower today but has contrarian potential next week ahead of earnings ...

Hims & Hers Health Inc is a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals, enabling them to access high-quality medical care for numerous conditions ...

Discover how Hims & Hers Health closed 2024 with strong growth, expanding weight-loss solutions, and innovation-focused investments in ...

Hims & Hers Health Inc is a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals, ...

Hims & Hers Health shares tumbled despite the telehealth provider beating fourth-quarter expectations and offering ...

Axon earnings are due this afternoon. The bar has been lowered for the Taser maker after Axon stock plunged in recent days.

US markets faced a tough week in 2025 amid inflation fears & weak economic data. Discover how top stocks like SMCI, BABA, and ...